Groton, CT / Worcester, MA — August 17th, 2020 — Enrich Therapeutics Inc., a device and application company focusing on unique single cell isolation technology, announced today that the company has been awarded a 24-month Small Business Innovation Research (SBIR) phase II grant in the amount of $1.7 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for further development of its proprietary single cell isolation platform.
Characterizing both functional and genetic heterogeneity among a pool of cells remains a major scientific challenge in immunology, cancer research, neurobiology, and developmental biology. Isolating cells with the same phenotype is the key to understanding such heterogeneity. Enrich proprietary technology targets the huge cell isolation market valued at more than $6B in 2020, and can be used to select and isolate cells based on organelle translocation, chromatin morphology, phagocytosis, synapse formation, protein co-localization, cell-cell interactions and other time-resolved cellular behaviors which cannot be achieved by current sorting platforms in a high-throughput manner.
During SBIR phase I of this project, which the grant was awarded within 10 months since the inception of Enrich Therapeutics, the company has established a unique, non-fluidic, technology to address the aforementioned unmet needs. The Enrich team completed the alpha version of prototype design and demonstrated its utility in critical POC applications, such as blood cell removal, phage enrichment on single beads, and isolation of tumor-killing immune cell clones. All phase I milestones were fully accomplished with convincing results, and the new award is intended to facilitate the translation of this promising technology to a commercial product and ultimately provide beneficial life science innovation to global biomedical researchers.
This new grant follows the company’s successful Phase I findings and will support the ongoing work of platform optimization and product development. Enrich team is tirelessly continuing the effort to bring its technology to market, besides the device, the company is planning to launch two accompanying application kits, Enrich-Live and Enrich-Seq, to unify the fragmented cell isolation market. The successful commercialization of Enrich products will enable thousands of cell biology labs and clinical settings to manipulate single cells as well as desired cell combinations on their computer screens with much-reduced cost and superior outcome.
The research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Award Number R44AI147734. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Enrich Therapeutics Inc.:
Enrich Therapeutics is a privately held company, founded in July 2018, focused on the development of novel single cell isolation platform along with the critical life science applications. Enrich Therapeutics aims to enhance global biomedical research at true single cell level with superior affordability and strength. Its static cell capture technology enables clone isolation under desired micro-environment with real-time monitoring. Enrich technology is making extensive impact in fields of basic biology, CAR-T, antibody, tumor genetics, etc., and is committed to isolating single clones from any physiologically relevant scenario. Additional information about the company may be found at www.enrichtx.com.
For more information: